Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients.

Literature DB >> 22669508

Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients.

Ozkan Gungor¹, Fatih Kircelli, Huseyin Toz.

Abstract

Atherosclerosis is an important contributor to increased cardiovascular burden in populations with and without renal disease. Paraoxonases (PON) are a group of enzymes that hydrolyse organophosphates. Recent evidence indicates a protective role for PON in patients with coronary artery disease and atherosclerosis. Although data are limited, the low enzyme activity found in patients with chronic kidney disease and renal transplants has been linked to atherosclerosis and arterial stiffness. In this paper, we review the emerging role of PON1 in the pathophysiology of atherosclerosis and arterial stiffness in patients with chronic kidney disease.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Aryldialkylphosphatase

Year: 2012 PMID： 22669508 DOI： 10.1007/s11255-012-0197-x

Source DB: PubMed Journal: Int Urol Nephrol ISSN： 0301-1623 Impact factor: 2.370

55 in total

1. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1.

Authors: M C Blatter-Garin; B Kalix; S De Pree; R W James
Journal: Diabetologia Date: 2003-03-22 Impact factor: 10.122

2. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.

Authors: Alejandro Gugliucci; Krista Mehlhaff; Eriko Kinugasa; Hiroaki Ogata; Ricardo Hermo; John Schulze; Satoshi Kimura
Journal: Clin Chim Acta Date: 2006-10-11 Impact factor: 3.786

3. Serum paraoxonase activity is decreased in uremic patients.

Authors: R Schiavon; E De Fanti; D Giavarina; S Biasioli; G Cavalcanti; G Guidi
Journal: Clin Chim Acta Date: 1996-03-29 Impact factor: 3.786

4. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study.

Authors: D Juretić; M Tadijanović; B Rekić; V Simeon-Rudolf; E Reiner; M Baricić
Journal: Croat Med J Date: 2001-04 Impact factor: 1.351

5. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients.

Authors: Alejandro Recio-Mayoral; Debasish Banerjee; Chris Streather; Juan Carlos Kaski
Journal: Atherosclerosis Date: 2011-02-18 Impact factor: 5.162

6. Serum paraoxonase and arylesterase activities in hemodialysis patients.

Authors: T Itahara; T Suehiro; Y Ikeda; M Inoue; T Nakamura; Y Kumon; M Kawada; K Hashimoto
Journal: J Atheroscler Thromb Date: 2000 Impact factor: 4.928

Review 7. Does uremia cause vascular dysfunction?

Authors: Philippe Brunet; Bertrand Gondouin; Ariane Duval-Sabatier; Laetitia Dou; Claire Cerini; Françoise Dignat-George; Noémie Jourde-Chiche; Angel Argiles; Stéphane Burtey
Journal: Kidney Blood Press Res Date: 2011-06-21 Impact factor: 2.687

8. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients.

Authors: O Hasselwander; D A Savage; D McMaster; C M Loughrey; P T McNamee; D Middleton; D P Nicholls; A P Maxwell; I S Young
Journal: Kidney Int Date: 1999-07 Impact factor: 10.612

9. Gln-Arg192 polymorphism of paraoxonase 1 is associated with carotid intima-media thickness in patients of type 2 diabetes mellitus of Chinese.

Authors: YaoMin Hu; HaoMing Tian; Rui Liu
Journal: Diabetes Res Clin Pract Date: 2003-07 Impact factor: 5.602